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Abstract
Background: Elevated serum bilirubin has been associated with reduced risk of cardiovascular disease (CVD).
However, serum bilirubin is also related with several potential confounders related to CVD, such as obesity.
Mendelian randomization has been proposed as a method to address challenges to validity from confounding and
reverse causality. It utilizes genotype to estimate causal relationships between a gene product and physiological
outcomes. In this report, we demonstrate its use in assessing direct causal relations between serum bilirubin levels
and CVD risk factors, including obesity, cholesterol, measures of vascular function and blood pressure.
Methods: Study subjects included 868 asymptomatic individuals. Study subjects were genotyped at the
UGT1A1*28 locus, which is strongly associated with bilirubin levels.
Results: Serum bilirubin levels were inversely associated with levels of several cardiovascular disease risk factors,
including body mass index (p = 0.003), LDL (p = 0.0005) and total cholesterol (p = 0.0002). In contrast, UGT1A1*28
genotype, a known cause of elevated bilirubin levels, was not significantly associated with any of these traditional
CVD risk factors. We did observe an association between genotype and brachial artery diameter (p = 0.003) and
cold pressor reactivity (p = 0.01).
Conclusions: Our findings imply that the observed association of serum bilirubin levels with body mass index and
cholesterol are likely due to confounding and suggest that previously established CVD benefits of increased
bilirubin may in part be mediated by the early regulation of vascular structure and reactivity.
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Background
Bilirubin is a metabolic byproduct of the breakdown of
hemoglobin degradation which itself must be metabo-
lized for appropriate excretion. High levels of bilirubin
are associated with decreased risk of coronary heart dis-
ease (CHD) and cardiovascular disease (CVD) [1]. While
the full spectrum by which bilirubin acts to protect
against CVD is not fully understood, there has been evi-
dence of protecting against oxidative stress by reducing
reactive oxygen species and possibly having additional
anti-atherogenetic properties [2,3]. Previous studies have
reported associations of serum bilirubin levels to cardio-
vascular disease risk factors, including total cholesterol
and blood pressure [4-6]. Serum bilirubin levels have
also been associated with socioeconomic and behavioral
CVD risk factors such as smoking and alcohol intake
[7,8]. However, the nature of these associations is
unclear, including the potential for residual confounding
among serum bilirubin levels and the associated CVD
risk factors due to factors measured poorly or not mea-
sured at all. Notably, the temporal ordering of variation
in these variables is hard to determine, raising chal-
lenges in separating ‘cause’ from ‘effect’.
Genotype is uniquely unaffected by most other epide-
miologic risk factors. If one accepts the notion that gen-
otypes are in a sense “randomly assigned” during
gamete formation, then using genetic variation as an
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any medium, provided the original work is properly cited.independent variable is attractive. Relationships between
genotype and outcomes have only limited susceptibility
to confounding and in particular are generally not sub-
ject to temporal misspecification of ‘cause’ and ‘effect’ (i.
e., reverse causality). Thus, genetic variation can be used
to aid in inferring causality between a gene product and
some outcome of interest. If a genetic variant is strongly
causal of a measured exposure, the variant can be used
as a proxy for exposure during modeling. This approach,
known as Mendelian randomization, can provide evi-
dence of causal inference between two variables [9].
Mendelian randomization has particular utility for eva-
luation of biomarkers that are highly influenced by a
single gene, are of interest in a disease process, and are
highly subject to confounding.
T h eg e n eU G T 1 A 1c o d e sf o ral i v e r - s p e c i f i cg l u c o r o -
nosyl transferase that converts bilirubin into a more
water-soluble form the body is better able to excrete.
Homozygosity at the polymorphic promoter repeat
locus UGT1A1*28 leads to decreased ability of the
UGT1A enzyme to metabolize bilirubin and subsequent
mild hyperbilirubinuria (also known as Gilbert’ss y n -
drome) [10-12]. Due to UGT1A1*28’s strong causal link
to bilirubin, use of the UGT1A1*28 genotype to more
precisely assess bilirubin - CVD risk factor associations
is an attractive and informative application of the Men-
delian randomization approach.
In this study, we describe use of the Mendelian rando-
mization approach to evaluate relations of serum biliru-
bin levels with CVD risk factors and subclinical
atherosclerosis in a sample of relatively healthy Old
Order Amish individuals from Lancaster County, PA.
We subsequently contrast the observed crude estimates
with those obtained utilizing Mendelian randomization
to illustrate its use. Separating causal from non-causal
relations provides evidence of bilirubin’sm e c h a n i s t i c
role in reducing CVD.
Methods
Study sample
The HAPI Heart Study began recruitment in 2003 with
the goal of identifying genes that interact with environ-
mental exposure to alter risk of CVD. The study was
carried out in an Old Order Amish community in Lan-
caster County, PA, and the study sample included 868
individuals aged 20 years and older who were relatively
healthy. Details of the study aims and recruitment pro-
cedures have been previously described [13]. Exclusion
criteria included severe hypertension (blood pressure >
180/105 mmHg), malignancy, and kidney, liver or
untreated thyroid disease. The study protocol was
approved by the Institutional Review Board at the Uni-
versity of Maryland, School of Medicine and informed
consent was obtained from each study participant.
Physical examinations were conducted at the Amish
Research Clinic in Strasburg, PA. Anthropometric vari-
ables, including height, weight, and blood pressure, were
assessed by study personnel. A fasting blood sample was
obtained for measurement of cholesterol and triglyceride
levels. Biochemical assays were performed by Quest
Diagnostics (Baltimore, MD). We also measured resting
brachial artery diameter. Brachial artery diameter was
measured using a linear array ultrasound utilizing a pre-
viously described technique [14,15]. Briefly, the left bra-
chial artery was imaged above the antecubital fossa in
the longitudinal plane by continuous 2D gray-scale ima-
ging with an 11 mHz ultrasound (Phillips HDI 5000CV).
Using guidelines established by the International Bra-
chial Artery Reactivity Task Force [16], all subjects were
fasting overnight and none were on any vasoactive med-
ications. The diameter of each artery was measured in a
blinded fashion by a trained technician. High resolution
B-mode ultrasound was carried out to image the right
and left common carotid arteries. IMT was measured
between lumen intima and media-adventitia interfaces
of the far wall by a single reader using an automated
edge detection system.
As part of the study protocol, participants underwent
a cold pressor test (CPT). While resting in supine state,
participants submerged their right hand and wrist to the
ulnar styloid in ice water for 2.5 min. Blood pressure
response to the stimulus was measured by calculating
the area under the curving using measurements of both
systolic and diastolic blood pressure at baseline (pre-
emersion), 1 min and 2.5 min.
Genotyping of UGT1A1*28 locus
The UGT1A1*28 locus was genotyped using the method
of Borlak et. al. [17] with slight modification to accom-
modate the Roche LightCycler 480. PCR was performed
o n3n go fg e n o m i cD N Aw i t h2u lo fL i g h t c y c l e r4 8 0
Genotyping Master in a total reaction volume of 10 ul.
All other reagents and concentrations were as per Bor-
lak; PCR conditions were: denaturation (95°C for 5
min), thermocycling for 45 cycles (95°C for 10 s, 56°C
for 20 s, 72°C for 20 s), single acquisition and (95°C for
2 min, 40°C for 2 min, 75°C continuous, 1 acquisition
per °C). Two alleles were present at this locus in the
Amish sample, the 6 allele and the 7 allele, with allele
frequencies of 0.57 and 0.43 respectively. The genotype
frequencies were slightly out of Hardy Weinberg equili-
brium (p = 0.04) due to an over representation of
heterozygotes.
Analytic approach
Mendelian randomization
The Mendelian randomization approach exploits the
fact that genotype precedes life events and is therefore
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that follow conception. To the extent that alleles are
randomly assigned at gamete formation, genotype may
be thought of analogously to assigned treatment in ran-
domized trials. As previously reviewed [9], Mendelian
randomization is an application of instrumental variable
analysis, and with certain assumptions the genotype-
phenotype relation can be utilized to attain un-con-
founded estimates of the relation between the gene pro-
duct and outcomes of interest. These assumptions
include an adequately strong relation between genotype
and phenotype and the absence of alternate pathways
from genotype to the outcome of interest (e.g. pleio-
tropy, population stratification, linkage disequilibrium).
The first assumption–a strong relation between geno-
type and phenotype–has been previously demonstrated
for UGT1A1*28 and bilirubin levels [10-12] and is
reflected in our data by the significant differences in
bilirubin levels by genotype. As long as these remaining
assumptions are met (see below), using genotype as the
exposure in analysis will be analogous to modeling
assigned treatment in an intention to treat analysis.
Causal assumptions
Figure 1 is a causal diagram portraying the assumptions
that underlie the relations among UGT1A1*28 genotype,
serum bilirubin levels and CVD risk factors. The true
causal relationship between serum bilirubin levels and
CVD risk factors is of interest, but this relationship may
be confounded by factors, either measured or unmea-
sured, as shown in Figure 1. These factors represent
causes of both the exposure and outcome, and failure to
appropriately address confounding will distort the rela-
tion of interest [18,19]. One can see that the relationship
between UGT1A1*28 and CVD risk factors are not
effected by the confounders. Under the assumption that
UGT1A1*28’s affect is primarily mediated by bilirubin,
it’s causal effect can be estimated. Any potential effect
o ft h eU G T 1 A 1e n z y m et og l u c u r o n i d a t eo t h e rs u b -
stance affecting our outcome measures, even if limited,
cannot be accounted for in this model.
Statistical methods
The principle of Mendelian randomization is illustrated
by contrasting the correlations observed between serum
bilirubin levels and CVD risk factors without considera-
tion for UGT1A1*28 genotype with the presumed
unconfounded results obtained between serum bilirubin
levels and CVD risk factors using a two-stage approach
that utilizes the genotype ~ outcome and genotype ~
bilirubin regressions [20]. The simple (potentially con-
founded) estimates were obtained by regressing serum
bilirubin levels (the independent variable) on each CVD
risk factor (the dependant variable) separately. The
Mendelian randomization estimate of the serum biliru-
bin-CVD risk factor correlation was obtained by dividing
the regression coefficient representing the genotype-
CVD risk factor effect by the regression coefficient
representing the genotype-serum bilirubin effect.
All of the participants of the HAPI Heart Study are
related. To address the correlations potentially existing
in phenotype by virtue of the fact that subjects are
related, we accounted for residual familial correlations
in phenotype using a variance component regression
framework. Specifically, we modeled variation in the
trait as a function of fixed covariates, a polygenic com-
ponent and a normally distributed error component.
The polygenic component was derived from the kinship
coefficient matrix which describes the relationship of
each pair of individuals in the sample. The software
package SOLAR was used for the analysis (Southwest
Foundation for Biomedical Research, San Antonio, TX).
Estimates of associations of CVD risk factors with biliru-
bin and with UGT1A1*28 genotype were evaluated
using this variance components approach. Bootstrap
sampling was used to estimate empirical 95% confidence
intervals for the Mendelian randomization estimates.
Since the existing literature shows that elevated bilirubin
was associated with decrease CVD, we a priori tested for
measured CVD risk factors within our cohort, as listed
in Table 1. These selected CVD risk factors are highly
correlated, so a strict bonferroni correction would
potentially result in excessive false negatives. Therefore
we elected to report uncorrected p-values.
Results
Sample characteristics
The 868 participants of the HAPI Heart Study ranged in
age from 20 years to 80 years at the time of the study,
and free of any known CVD at that time. Table 2 gives
the clinical characteristics of the sample.
Table 3 shows gender, age and bilirubin levels by
UGT1A1*28 genotype. Age was not significantly asso-
ciated with genotype although a significantly higher per-
centage of individuals with the 7/7 genotype were male
when compared to carriers of the 6 allele (P = 0.03).
Figure 1 A diagram representing assumed relations in the
causal system. In this figure, the relation between bilirubin and
CVD risk factors is of interest, but is potentially confounded by
measured or unmeasured factors. Genotype at the UGT1A1*28 locus
affects CVD risk factors only through its relation with bilirubin and is
not subject to confounding. The CVD risk factors listed in Table 1
were considered.
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determination, and the UGT1A1*28 locus is not linked
to the sex chromosomes. Thus, the difference in gender
distribution by genotype is most likely not a causal asso-
ciation but rather a chance occurrence; however, since
gender differences are also a likely cause of variation of
many of the traits further studied, statistical control of
gender is warranted. As gender is unlikely to have any
causes among other factors considered, statistical
adjustment will not result in analysis induced bias, also
known as collider stratification bias [21].
Association of UGT1A1*28 genotype with serum Bilirubin
As expected, genotype at the UGT1A1*28 locus was
strongly associated with bilirubin levels, Table 3. Among
those with 7/7 genotype, serum bilirubin level were
nearly twice those with 6/7 or 6/6 (P < 0.0001 when
controlling for gender and age effects and accounting
for the expected correlation in the trait due to familial
relatedness of the study participants). UGT1A1*28 geno-
type accounts for 45% of the variation in bilirubin in
this population (F-statistic = 682.12). This strong asso-
ciation between genotype and phenotype supports the
first condition for use of Mendelian randomization.
Association of serum Bilirubin levels with CVD risk factors
Simple (i.e., non-Mendelian randomization) associations
of serum bilirubin levels with selected CVD risk factors,
Table 1 Observational estimates (95% confidence interval) of the phenotype-bilirubin association and the
corresponding variance components p-value, mean phenotype value (standard deviation) and significance test of
mean difference comparing 7/7 homozygotes with carriers of the 6 allele and point estimates and 95% confidence
interval for estimates of effect using Mendelian randomization
Traditional Approach Mendelian Randomization Approach
Trait Estimate (95% CI) p 6/6
mean (SD)
6/7
mean (SD)
7/7
mean (SD)
7/7 vs 6 carriers p Estimate (95% CI)
Body Mass Index (kg/m2) -1.5 (-2.4, -0.5) 0.003 26.6 (4.7) 26.5 (4.3) 27.0 (4.6) 0.43 0.6 (-0.5, 1.6)
Waist Circumference (cm) -1.9 (-4.2, 0.4) 0.11 87.5 (11.2) 86.9 (10.8) 88.0 (11.1) 0.16 2.4 (0.0, 5.2)
SBP (mmHg) -2.8 (-5.9, 0.3) 0.08 122.4 (14.3) 120.9 (15.4) 120.6 (13.5) 0.50 -1.9 (-4.8, 1.9)
DBP (mmHg) -1.7 (-3.5, 0.1) 0.07 77.7 (8.5) 76.2 (8.6) 76.4 (8.9) 0.74 0.7 (-2.6, 1.8)
Heart Rate (/s) -0.9 (-3.0, 1.3) 0.43 79.0 (8.5) 78.0 (7.8) 78.4 (8.9) 0.77 -0.5 (-3.1, 2.3)
Triglycerides (mg/dl) -7.4 (-16.2, 1.4) 0.10 68.4 (42.7) 67.0 (40.5) 71.9 (41.6) 0.39 5.7 (-4.1, 15.8)
Fasting HDL Cholesterol (mg/dl) -1.4 (-4.4, 1.7) 0.38 56.4 (14.3) 55.6 (14.5) 55.2 (14.9) 0.28 -2.5 (-5.7, 0.7)
Fasting LDL Cholesterol (mg/dl) -15.9 (-24.8, -7.0) 0.0005 141.0 (44.5) 137.5 (41.7) 139.4 (44.6) 0.62 -3.4 (-13.9, 8.6)
Fasting Total Cholesterol (mg/dl) -18.6 (-28.3, -8.9) 0.0002 211.1 (48.5) 206.5 (45.9) 209.0 (46.8) 0.54 -4.6 (-15.4, 7.5)
Common Carotid IMT (mm) -0.03 (-0.06, 0.01) 0.12 0.6 (0.2) 0.6 (0.2) 0.6 (0.2) 0.65 0.0 (-0.03, 0.05)
C Reactive Protein (mg/l) -0.9 (-1.9, 0.1) 0.07 1.9 (3.8) 2.3 (6.2) 1.7 (2.1) 0.31 -0.8 (-1.4, 0.1)
Pulse Wave Velocity (m/s) -0.08 (-0.4, 0.2) 0.57 5.3 (1.3) 5.2 (1.1) 5.4 (1.3) 0.17 0.3 (0.0, 0.6)
CPT SBP (mmHg*min) 1.4 (-2.2, 4.9) 0.45 28.8 (17.0) 27.2 (15.6) 31.6 (16.3) 0.02 6.1 (2.1, 10.4)
CPT DBP (mmHg*min) 1.7 (-0.7, 4.2) 0.17 16.5 (11.8) 15.8 (10.5) 18.7 (11.6) 0.01 5.0 (2.4, 8.1)
Flow Mediated Dilation (%) 0.7 (-0.8, 2.1) 0.37 9.7 (5.7) 10.5 (5.8) 11.3 (6.4) 0.12 1.6 (-0.2, 3.2)
Brachial Artery Diameter (mm) -0.5 (-1.8, 0.7) 0.40 28.2 (5.0) 27.7 (5.4) 26.2 (4.6) 0.003 -1.9 (-2.7, -1.0)
Abbreviations: CI confidence interval, SD standard deviation, MR Mendelian randomization, CPT cold pressor test
Table 2 Clinical characteristics (mean (SD)) of the 868 Old
Order Amish enrolled in the HAPI Heart Study, Lancaster
County PA
Characteristic Men
(n = 460)
Women
(n = 408)
Age (yrs) 42.2 (13.6) 45.4 (14.2)
BMI (kg/m
2) 25.6 (3.2) 27.8 (5.5)
Total Cholesterol (mg/dl) 202.5 (44.3) 215.7 (49.0)
Triglycerides (mg/dl) 63.9 (1.7) 73.8 (45.4)
SBP (mmHg) 121.5 (12.6) 121.4 (16.9)
DBP (mmHg) 77.6 (8.8) 75.8 (8.4)
Diabetes (%) 0.9 1.0
Current Smokers (%)* 20.0 0.0
Lipid Lowering Meds (%)** 1.0 1.0
Antihypertensive Meds (%)** 0.2 0.3
* Indicates use of cigarettes, cigars and pipes
** Medication use assessed at the time of recruitment, before participants
were asked to discontinue use
Table 3 Gender, age and bilirubin levels stratified by
UGT1A1*28 genotype of Old Order Amish enrolled in the
HAPI Heart Study, Lancaster County, PA
Trait 6/6
(n = 296)
6/7
(n = 392)
7/7
(n = 173)
7/7 vs.
6/6-6/7
Gender,% male 58.1% 53.1% 46.2% 0.03
Age, yrs (SD) 44.0 (13.6) 43.0 (14.3) 44.6 (13.7) 0.49
Bilirubin, mg/dL (SD) 0.42 (0.14) 0.49 (0.18) 0.99 (0.42) < 0.0001
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vascular reactivity were evaluated. Regression coeffi-
cients obtained from these analyses, their 95% confi-
dence intervals, and p-values evaluating whether these
estimates differ from zero are shown in Table 1. Con-
sistent with previous studies showing bilirubin to be
inversely associated with CVD and CHD, we observed
serum bilirubin levels in this study also to be inversely
associated with a variety of CVD risk factors. Specifi-
cally, serum bilirubin levels were negatively associated
with BMI (P = 0.003), LDL cholesterol (P = 0.0005)
and total cholesterol (P = 0.0002). Higher bilirubin
levels correlate weakly with lower IMT (P =0 . 1 2 ) .
These associations (or lack thereof) may be causal or
non-causal and may be subject to confounding or
reverse causality (i.e., measured bilirubin levels affected
by the CVD risk factor).
Association of UGT1A1*28 genotype with CVD risk factors
We hypothesized that genotype would be related to
CVD risk factors primarily through its affect on serum
bilirubin levels. Mean values (and standard deviation) of
t h ec o n s i d e r e dC V Dr i s kf a c t o r sb yg e n o t y p ea r ep r e -
sented also in Table 1. Genotype was not associated
with either BMI (P = 0.43) or waist circumference (P =
0.16). Similarly there is no significant difference in
blood pressure (SBP P = 0.50, DBP P = 0.74) or choles-
terol levels (HDL P = 0.28, LDL P = 0.62) across geno-
type groups. The 7/7 genotype, which corresponds to
higher serum bilirubin levels, was associated with a sig-
nificantly smaller brachial artery diameter (P = 0.003)
and with cold pressor reactivity (p = 0.01).
Association of serum Bilirubin levels with CVD risk
factors: Mendelian randomization approach
The right-most column of Table 1 shows the two-stage
estimate (and 95% confidence interval) of the serum
bilirubin-CVD risk factor association derived from the
Mendelian randomization approach that accounts for
UGT1A1*28 genotype. To the extent that Mendelian
randomization assumptions are upheld, these estimates
m a yb ec o n s i d e r e da su n c o n f o u n d e db ya l lm e a s u r e d
and unmeasured factors that fit the role of confounders
in Figure 1 considered.
Discordance between the simple and Mendelian ran-
domization estimates of the serum bilirubin-CVD risk
factor relationship suggests the presence of confounding
[22,23]. Some results indicate that confounding is severe
enough to reverse the direction of the point estimates,
potentially leading to qualitative differences in inference.
For example, point estimates of the crude associations
of BMI (-1.5, P = 0.003), waist circumference (-1.9, P =
0.11) and diastolic blood pressure (-1.7, P = 0.07) chan-
ged direction in the Mendelian randomization analysis
(BMI: 0.6, P = 0.28; waist circumference: 2.4, P = 0.05;
DBP: 0.7, P = 0.68).
Discussion
Associations between serum bilirubin and multiple CVD
risk factors have been previously reported, but attribu-
tion of causality has been challenged by the potential for
confounding and uncertainty regarding temporal order-
ing [24]. Importantly, Lin et. al. [1] utilized genotype at
the UGT1A1*28 locus to suggest a causal role for biliru-
bin in cardiovascular and coronary heart diseases. Most
notably, using longitudinal data over 24 years of follow
up, they demonstrated a striking unconfounded associa-
tion with CVD events. While that study supports the
hypothesis that increased bilirubin levels cause a
decreased risk of CVD, it did not provide estimates of
the causal relation of bilirubin with markers of cardio-
vascular disease burden and hence did not help identify
the underlying pathway by which bilirubin might protect
against CVD events. In this study, using Mendelian ran-
domization, we attempt to extend previous studies by
exploring the association between bilirubin and sub-clin-
ical markers of vascular reactivity and CVD burden in
“healthy” subjects, to help delineate potential early
mechanistic pathways related to bilirubin. Of note, we
find an association between bilirubin and brachial artery
diameter and cold pressure reactivity, while utilizing
genotype as an instrumental variable per Mendelian
Randomization. This association between bilirubin and
brachial artery diameter was not present in our data
using the traditional regression approach, most likely
due to the presence of confounding factors. In this case,
it appears that confounding acts to hide or underesti-
mate a potentially causal association. If one believes
UGT1A1*28 locus is a reliable instrument of bilirubin
levels, these data provide evidence that bilirubin may act
on CVD via mechanism associated with brachial artery
diameter.
While baseline brachial artery diameter had tradition-
ally been measured to derive brachial flow mediated
dilation measures as a surrogate of endothelial function,
several studies have demonstrated an independent asso-
ciation between brachial artery diameter with coronary
artery calcification [25], serum uric acid [26], blood
pressure, serum lipids, smoking and glucose [27,28], car-
otid IMT [29], pregnancy [30], severity of chronic heart
failure [31], angiographic measures of coronary artery
disease [32] and CVD events in a cohort of over 2500
subjects [33]. Brachial artery size is also a determinant
not only of both FMD and time to peak FMD, but also
of non-endothelial related vasodilatory capacity [34].
These studies clearly demonstrate repeatable and signifi-
cant associations between brachial artery diameter and
both CVD risk factors, outcomes and measures of
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it may be more predictive of CVD than FMD measures.
As such, our finding of smaller brachial artery diameter
in hyperbilirubinemic subjects is consistent with the sig-
nificant decrease in CVD disease noted in subjects with
Gilbert’s syndrome [1,35] and raises a potential new
mechanism associated with the CVD protective effects
of bilirubin, separate from its described antioxidant and
anti-inflammatory properties [24,36]. The CPT, by mea-
suring blood pressure change in response to cold stimu-
lus, has been used as a measure of global sympathetic
activity and/or response. Our study shows a modest
association between bilirubin and increased CPT reac-
tivity. While several studies have shown that increased
reactivity in healthy populations may be associated
with increased probability for hypertension, the results
have not always been consistent, notably in healthy
cohorts such as in this study [37,38]. One reason for
this could be that increased CPT reactivity may reflect
either increased sympathetic activity, which is likely
not protective of CVD or may be due to increased
reactivity of blood vessels to sympathetic stimulus,
which may be a reflection of healthy vasculature and
less CVD. Indeed, ageing and obesity are associated
with decreased vascular response to sympathetic activ-
ity and norepinephrine [39-41]. As such, it is plausible
that higher bilirubin levels may be associated with
increased vascular response capacity as opposed to an
increase in sympathetic neural activity. The lack of
association between the UGT1A1*28 genotype and
heart rate also suggests no direct increase in baseline
sympathetic activity. Mechanistic pathways for the
well noted observation of smaller brachial artery dia-
meter with decreased measures of CVD have not yet
been elucidated. We did not find an association
between the UGT1A1*28 genotype and markers of
more advance vascular pathology such as PWV or
IMT. This could be secondary to the absence of any
such association or also because we studied a rela-
tively young and healthy population with a low CVD
disease burden.
Conclusions
In conclusion, we have utilized Mendelian randomiza-
tion techniques to address confounding in the estima-
tion of bilirubin’s causal relationship with known CVD
risk factors. Our data suggest that many of the associa-
tions from observational epidemiology studies reported
in the literature are subject to un-accounted for con-
founding and/or reverse causality. Of the tested risk fac-
tors, brachial artery diameter and to a lesser degree
CPT reactivity were significantly associated with geno-
type at the UGT1A1*28 locus, providing compelling evi-
dence that bilirubin affects CVD through pathways
associated with artery size such as vasomotor tone, reac-
tivity and possibly arterial wall structure.
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